A phase I and pharmacokinetic (PK) study of the novel mushroom-derived cytotoxin, MGI 114, in combination with irinotecan in patients with advanced cancer.

被引：0
|
作者：
Eckhardt, SG
Kuhn, JG
Britten, CD
Weitman, S
Baker, SD
MacDonald, JR
Newman, A
Smith, S
Von Hoff, DD
Rowinsky, EK
机构：
[1] MGI PHARMA, Minnetonka, MN USA
[2] Canc Therapy & Res Ctr, San Antonio, TX 78229 USA
来源：
CLINICAL CANCER RESEARCH | 1999年 / 5卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
319
引用
收藏
页码：3793S / 3793S
页数：1
相关论文
共 50 条
  • [41] Phase I-II study of irinotecan in combination with mitomycin C in patients with advanced gastrointestinal cancer
    Gil-Delgado, MA
    Antoine, EC
    Guinet, F
    Bassot, V
    Grapin, JP
    Benhammonda, A
    Adam, R
    Castaing, D
    Bismuth, H
    Khayat, D
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2001, 24 (03): : 251 - 254
  • [42] Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer
    Patnaik, A
    Rowinsky, EK
    Tammara, BK
    Hidalgo, M
    Drengler, RL
    Garner, AM
    Siu, LL
    Hammond, LA
    Felton, SA
    Mallikaarjun, S
    Von Hoff, DD
    Eckhardt, SG
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (23) : 3974 - 3985
  • [43] A phase I pharmacokinetic study of ONT-093 in combination with paclitaxel in patients with advanced cancer
    Chi, KN
    Chia, SK
    Sikic, B
    Dixon, R
    Newman, M
    Wacher, VJ
    Toyonaga, B
    Hoth, D
    Gelmon, KA
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S156 - S156
  • [44] Temozolomide in patients with advanced cancer: Phase I and pharmacokinetic study
    Rudek, MA
    Donehower, RC
    Statkevich, P
    Batra, VK
    Cutler, DL
    Baker, SD
    PHARMACOTHERAPY, 2004, 24 (01): : 16 - 25
  • [45] Phase I safety and pharmacokinetic (PK) study of sunitinib (S) in combination with ifosfamide (I) in patients (pts) with advanced solid tumors (STs)
    Hamberg, P.
    Steeghs, N.
    Loos, W. J.
    van der Biessen, D. J.
    den Hollander, M. A.
    Tascilar, M.
    Verweij, J.
    Gelderblom, H.
    Sleijfer, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [46] Phase I/II study of oral uracil/tegafur (UFT®), leucovorin and irinotecan in patients with advanced colorectal cancer.
    Hill, M
    Mackay, H
    Cunningham, D
    Glasspool, R
    Price, T
    Campbell, S
    Massey, A
    Bailey, S
    Martin, C
    Twelves, C
    ANNALS OF ONCOLOGY, 2000, 11 : 45 - 45
  • [47] Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors
    Jimeno, Antonio
    Rudek, Michelle A.
    Purcell, Thomas
    Laheru, Daniel A.
    Messersmith, Wells A.
    Dancey, Janet
    Carducci, Michael A.
    Baker, Sharyn D.
    Hidalgo, Manuel
    Donehower, Ross C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (03) : 423 - 433
  • [48] A phase I trial of fixed-dose-rate (FDR) gemcitabine and irinotecan combination in patients with advanced pancreatic and biliary cancer.
    Sun, W
    Theobald, ME
    Hershock, D
    Haller, DG
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 341S - 341S
  • [49] Phase I dose-escalation and pharmacokinetic study of antrubicin in patients with recurrent advanced lung cancer.
    Okamoto, I
    Hamada, A
    Matsunaga, Y
    Sasaki, JI
    Fujii, S
    Uramoto, H
    Yamagata, H
    Mori, I
    Kishi, H
    Semba, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 151S - 151S
  • [50] Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors
    Antonio Jimeno
    Michelle A. Rudek
    Thomas Purcell
    Daniel A. Laheru
    Wells A. Messersmith
    Janet Dancey
    Michael A. Carducci
    Sharyn D. Baker
    Manuel Hidalgo
    Ross C. Donehower
    Cancer Chemotherapy and Pharmacology, 2008, 61 : 423 - 433
12345